MAPK1 and brain ischemia: ERK phosphorylation mediated by preconditioning (Kovalska et al., 2014) and by numbers of neuroprotective compounds, such as dexmedetomidine, an α2-adrenergic agonist, (Du et al., 2009; Zhu et al., 2013) reduces cell damage in brain ischemia.